LAS VEGAS, Oct. 10, 2017 -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company," "CV Sciences," "our" or "we"), today announced that its industry-dominating brand of hemp-derived cannabidiol (CBD) oil finished products, PlusCBD Oil™, will be exhibiting at the Academy of Integrative Health & Medicine (AIHM) Annual 2017 Conference, held on October 22-25, 2017 at Paradise Point Resort & Spa in San Diego, California. This will be the Company’s third time exhibiting at this forward-thinking healthcare Conference and Expo.
Known as “The Integrative Health & Medicine Conference of the Year,” AIHM Conference brings together over 1,100 doctors, health clinicians, researchers and students to learn from visionaries in the field of integrative health, earn continuing education credits and network with likeminded professionals. This community-centric conference features lectures, panels, small group discussions, workshops, evening events and experiential programs. Over the last three years, CV Sciences’ consumer products division has focused on distributing their PlusCBD Oil™ brand to healthcare providers nationwide.
"AIHM’s Annual Conference brings together thought leaders in the field of integrative health and nutritional medicine, and showcases companies like CV Sciences who share in that vision," comments Stuart Tomc, VP of Human Nutrition at CV Sciences. "The demand for phytocannabinoids such as CBD is here, and practitioners continue to seek out reliable information on current practical and nutritional benefits of hemp-derived CBD. We are excited to continue to showcase our growing array of products showing the tremendous potential hemp-derived CBD may hold for overall health and look forward to educating attendees at this year’s Conference."
VISIT BOOTH 15: CV Sciences invites attendees to visit Booth 15 to learn more about their botanical-based CBD product line. The Company will additionally feature its brand of practitioner-exclusive products available only to healthcare providers nationwide. Also, CV Sciences will be offering exclusive trade show discounts and show specials to practitioners attending the show.
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
CONTACT: Robert Haag, Managing Director IRTH Communications [email protected] 866-976-4784


Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 



